Reference health
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
00224-x/badge.svg){kind=icon}
63/63 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
69 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 63 checked references that resolve
resolves10.1038/205698a0
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
resolves10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L
Charles F. Kettring prize. Fundamental studies with cisplatin
resolves10.1007/978-3-642-49306-5_12
Clinical Evalutions of Toxic Effects of cis-Platinum (II) Diamminedichloride
resolves10.1016/S0022-5347(17)59652-4
Diamminodichloroplatinum in the Chemotherapy of Testicular Tumors
resolves10.7326/0003-4819-87-3-293
<i>Cis</i>-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer
resolves10.1136/bmj.303.6807.884
Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
resolves10.1136/bmj.311.7010.899
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
resolves10.1016/S1054-3589(08)60247-1
cis-Diamminedichloroplatinum (II): A Metal Complex with Significant Anticancer Activity
resolves10.1016/0959-8049(94)00513-5
Cycloplatam: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin
resolves10.1007/BF00296754
Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease
resolves10.1007/BF00258128
In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera
resolves10.1016/0305-7372(85)90015-5
Preclinical studies identifying carboplatin as a viable cisplatin alternative
resolves10.1007/BF00257742
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
resolves10.1200/JCO.1992.10.4.520
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
resolves10.1200/JCO.1989.7.11.1748
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
resolves10.1097/00001813-199410000-00003
A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count
resolves10.1093/jnci/87.8.573
Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient Characteristics
resolves10.1038/bjc.1993.73
A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days
resolves10.1097/00001813-199302000-00007
A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion
resolves10.1038/bjc.1995.252
Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer
resolves10.1007/BF00873809
A Clinical Screening Cooperative Group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer
resolves10.1007/978-1-4613-1717-3_75
Two New Water Soluble Platinum Complexes — CL 286, 558 and CL 287, 110
resolves10.1093/oxfordjournals.annonc.a058026
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex
resolves10.1016/0959-8049(93)90386-T
Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex
resolves10.1007/BF01624436
Phase II trial of zeniplatin (CL 286 558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy
resolves10.1007/BF00685681
Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4-butanediamine-N,N 1) platinum in patients with metastatic solid tumors
resolves10.1111/j.1349-7006.1991.tb01909.x
Toxicological and Tumoricidal Evaluations of a New Platinum Complex, (–)‐(R)‐2‐Aminomethy lpyrrolidine (1,1‐cyclobutanedicarboxylato) platinum (II) Monohydrate, in Rats
resolves10.1093/jnci/82.12.1046
Phase I Trial of 5-Day Continuous Venous Infusion of Oxaliplatin at Circadian Rhythm-Modulated Rate Compared With Constant Rate
resolves10.1016/0959-8049(93)91524-O
Phase II study of oxaliplatin (L-OHP) in patients with advanced non small cell lung cancer (NSCLC): Preliminary results
resolves10.1016/0959-8049(93)91687-G
Preliminary phase II trial of oxaliplatin (L-OHP) in malignant astrocytomas
resolves10.1093/oxfordjournals.annonc.a010500
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
resolves10.1016/0959-8049(95)95987-H
738 Oxaliplatin (L-OHP®): Summary of results in advanced colorectal cancer (ACC)
resolves10.1200/JCO.1998.16.8.2739
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
resolves10.1093/jnci/86.21.1608
Chronomodulated Versus Fixed-Infusion—Rate Delivery of Ambulatory Chemotherapy With Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients With Colorectal Cancer Metastases: a Randomized Multi-institutional Trial
resolves10.1007/BF00254097
Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II)
resolves10.1007/978-1-4613-2837-7_25
Phase I and Early Phase II Trials of 4′Carboxyphthalato (1,2 Diaminocyclohexane) Platinum (II)
resolves10.1007/BF00685835
Preclinical antitumor activity of orally administered platinum (IV) complexes
resolves10.1007/s002800050624
Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models
resolves10.1007/BF00685793
A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration
resolves10.1200/JCO.1997.15.7.2691
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
resolves10.1016/S0169-5002(97)89652-3
272 A phase I study of JM-216 with concomitant radiation therapy for patients (pts) with malignancies of the chest
resolves10.1023/A:1008245709924
Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation
resolves10.1016/S0300-9084(78)80568-9
Anti-tumour platinum complexes : relationships between chemical properties and activity
resolves10.1016/0277-5379(91)90470-X
Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study
resolves10.1016/S0959-8049(05)80327-2
Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung
resolves10.1007/BF00194600
A Phase II study of CHIP in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study)
resolves10.1097/00000421-198908000-00016
Phase II Study of Iproplatin (CHIP) in Previously Treated Small-Cell Lung Cancer
resolves10.1200/JCO.1991.9.7.1131
A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer.
resolves10.1093/oxfordjournals.annonc.a057796
Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma
The 69 references without a DOI — listed, not checked
no DOI — not checkedBeitrag zur konstitution anorganischer verbindingen
no DOI — not checkedHill JM, Speer RJ, Loeb E, MacLellan A, Hill NO, Khan A. Clinical experience with cisplatinous diammine dichloride (PPD). In Hejzlar M, ed. Advances in Antimicrobial and Antineoplastic Chemotherapy. Prague, Urban & Schwartzenberg, 1971, 255–257.
no DOI — not checkedCis-platinum (II) diamminedichloride: clinical review of a new cancer chemotherapeutic agent
no DOI — not checkedAmelioration of renal toxicity of high dose cis-platinum diammine dichloride (CPDD) by mannitol induced diuresis
no DOI — not checkedA new method to prevent toxicity with high doses of cis diammine platinum (therapeutic efficacy in previously treated widespread and recurrent testicular tumors)
no DOI — not checkedAntitumor activity of 254-S, a platinum complex, in rodents
no DOI — not checkedAriyoshi Y, Ota K, Wakui A, et al. Phase I study of (glycolato-0,0′) diammine platinum (II) (254-5). Proc Am Soc Clin Oncol 1988, 7, 59.
no DOI — not checkedSasaki Y, Amano T, Morita M, et al. Phase I study and pharmacological analysis of cis-diammine (glycolato) platinum (254-S; NSC 3751010) administered by 5-day continuous intravenous infusion. Cancer Res 1991, 51, 1472–1477.
no DOI — not checkedOta K, Miyake H, Inuyama I, et al. Clinical evaluation of cis-diammine (glycolato) plat 254-S, a new anticancer platinum complex. Proc NCI-EORTC Symp New Drugs in Cancer Therapy 1991, 7, 340.
no DOI — not checkedA randomized comparative study of 254-S/vindesine (VDS) vs. cisplatin (CDDP)/VDS for advanced non-small cell lung cancer (NSCLC)
no DOI — not checkedA phase I and pharmacokinetic trial of cycloplatam in patients with refractory solid tumors
no DOI — not checkedPhase II of cycloplatam in advanced ovarian carcinoma
no DOI — not checkedNew analog of platinum-cycloplatam—treatment of breast cancer
no DOI — not checkedKim NK, Bang Y-J, Heo DS, et al. A phase I clinical and pharmacokinetic study of SKI 2053 R, a new platinum analog in patients with malignancies. Proc Am Soc Clin Oncol 1995, 14, 479.
no DOI — not checkedKim NK, Im SA, Jung CW, et al. An active new platinum analog SKI 2053 R in patients with advanced gastric adenocarcinoma: phase II clinical trial. Proc Am Soc Clin Oncol 1997, 16, 294a.
no DOI — not checkedOrgano-platinum complexes as antitumor agents
no DOI — not checkedPinedo HM, Ten Bokkel Huinink WW, Van Der Vijgh WJF, et al. Phase I study of ethylenediaminoplatinum (II) malonate (JM-40). Proc Am Soc Clin Oncol 1984, 3, 40.
no DOI — not checkedKavanagh JJ. Carboplatin in refractory epithelial ovarian cancer. In Bunn PA Jr, Canetta R, Ozols RF, Rozencweig M, eds. Carboplatin, Current Perspectives and Future Directions. Philadelphia, W.B. Saunders, 1990, 141–152.
no DOI — not checkedKearns CM, Belani CP, Erkmen K, et al. Reduced platelet toxicity with combination carboplatin and paclitaxel; pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc Am Soc Clin Oncol 1995, 14, 170.
no DOI — not checkedCreaven PJ, Raghavan D, Perez RP, et al. Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. Sem Oncol 1996, 6(Suppl 16), 26–31.
no DOI — not checkedPhase I study of the new platinum complex D19466 on a single intermittent schedule
no DOI — not checkedFeibig HH. Phase I and II studies with lobaplatin. Proc Int Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1995, 7, S127.
no DOI — not checkedSchmoll HJ, Kohne CH, Papageorgiou E, et al. Single agent lobaplatin is active in patients with esophageal squamous cell carcinoma. A phase II evaluation. Proc Am Soc Clin Oncol 1995, 14, 201.
no DOI — not checkedRolland F, Douillard JY, Adenis A, et al. Lobaplatin in combination with 5-fluorouracil in patients with esophageal carcinoma: a phase I/II feasibility study. Proc Int Congress on Anti-Cancer Treatment 1996, 6, 320.
no DOI — not checkedCeulemans F, Duprez P, Vindevogel A, et al. Enloplatin (CL 287,110): phase I study in patients with advanced solid tumors. Proc Intl Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1991, 7, 168.
no DOI — not checkedKudelka A, Edwards C, Freidman R, et al. Phase II study of enloplatin for patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 1993, 12, 269.
no DOI — not checkedPreclinical characterization of the in vitro and in vivo activity of [1,1′-cyclobutane dicarboxylato (2-)-0,0′](2-methyl 1-1,4-butanediamine-N,N′) Pt (NK-121/CI-973)
no DOI — not checkedHino M, Niitani H, Hasegawa K, et al. Phase I study of new platinum compound, NK121. In Rubinstein E, Adam D, eds. Recent Advances in Chemotherapy. Jerusalem, E. Lewin-Epstein Ltd., 1989, 745.1–745.2.
no DOI — not checkedO’Dwyer PJ, Hudes GR, Walczak J, et al. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule. Cancer Res 1992, 52, 6746–6753.
no DOI — not checkedRoberts J, Kudelka A, Spriggs D, et al. Phase II study of CI-973 in advanced ovarian cancer. Proc An Soc Clin Oncol 1994, 13, 269.
no DOI — not checkedClinical trials of 254-S, NK121, and TRK-710
no DOI — not checkedClinical trials of oxaliplatin and DWA 2114R
no DOI — not checkedPhase II trial of DWA2114R for ovarian cancer
no DOI — not checkedKato T, Yakushiji M, Nishimura H, et al. Phase III study of DWA2114R for ovarian cancer. Jpn J Cancer Chemother 1992, 19, 1285–1293.
no DOI — not checkedIn vitro cytotoxity studies of oxaliplatin in human tumor cell lines
no DOI — not checkedMathé G, Kidani Y, Triana K, et al. A phase I trial of trans-1-diaminocyclohexane oxalatoplatinum (1-OHP). Biomedicine & Pharmacotherapy 1986, 40, 372–376.
no DOI — not checkedEriguchi M, Sekiguchi M, Fujii Y, et al. Clinical study for a new platinum complex 1-OHP: oxalato (1-1, 2-diaminocyclohexane) platinum (II) against solid tumors. Proc NCI-EORTC Symposium on New Drugs in Cancer Therapy 1991, 7, 343.
no DOI — not checkedRotarski M, Brienza S, Gastiaburu J, et al. Oxaliplatin (l-OHP): a new platinum analog: active in refractory/relapsed intermediate and low grade non-Hodgkin lymphoma. Proc Am Soc Clin Oncol 1993, 12, 375.
no DOI — not checkedGarufi C, Nistico C, Brienza S, et al. Oxaliplatin (l-OHP) activity in anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 1997, 16, 170a.
no DOI — not checkedGastiaburu J, Misset JL, Brienza S, et al. Early phase II trial of trans-1-diammino cyclohexane (l-OHP) in malignant melanoma, advanced ovarian cancer, low grade non-Hodgkin’s lymphoma. Proc Am Assoc Cancer Res 1992, 33, 538.
no DOI — not checkedPhase II trial of oxaliplatin (l-OHP) in locoregional advanced, recurrent and/or metastatic head and neck squamous cell carcinoma
no DOI — not checkedde Braud F, Munzone E, Nolé F, et al. Oxaliplatin (l-OHP) as a second line treatment in metastatic colorectal cancer patients clinically resistant to fluorouracil. Proc Am Assoc Cancer Res 1997, 38, 520.
no DOI — not checkedGiacchetti S, Zidani R, Perpoint B, et al. Phase III trial of 5-fluorouracil, folinic acid, with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997, 16, 229a.
no DOI — not checkedMisset JL, Chollet P, Vennin P, et al. Multicentre phase II–III trial of oxaliplatin versus cisplatin, both in association with cyclophosphamide, in the treatment of advanced ovarian cancer: toxicity efficacy results. Proc Am Soc Clin Oncol 1997, 16, 354a.
no DOI — not checkedPhase I clinical and pharmacology study of liposome-entrapped cis-bis-neodexanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (1-NDDP)
no DOI — not checkedPerez-Soler R, Shin DM, Siddik ZH, et al. Phase I clinical and pharmacological study of liposome-entrapped (L-NDDP) administered intrapleurally in patients with malignant pleural effusions. Proc Am Soc Clin Oncol 1996, 15, 492.
no DOI — not checkedAntitumor activity of TRK-710, a new platinum complex having activity against cisplatin-resistant tumours
no DOI — not checkedCytometric characterization of cisplatin and a new platinum analog, TRK-710
no DOI — not checkedKhan A, Speer RJ, Ridgway H, et al. Pre-clinical and phase I clinical trial with bis (pyruvato) 1,2-diaminocyclohexane platinum (II). In Hacker MP, Douple EB, Krakoff IH, eds. Platinum Coordination Complexes in Cancer Chemotherapy. Boston, Martinus Nijhoff, 1983, 255.
no DOI — not checkedPharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane (isocitrato) platinum (II)
no DOI — not checkedNew platinum analogs
no DOI — not checkedLack of cross-resistance between certain platinum coordination compounds in mouse leukemia
no DOI — not checkedde Jon WH, Steerenberg PA, Vos JG, et al. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexane platinum (II) sulfate, and of cis-diammine dichloroplatinum (II) in immunocytoma model in the LOU/M rat. Cancer Res 1983, 43, 4927–4934.
no DOI — not checkedFranks CR, Materman E, Nys G, et al. TN06 (1,1-diamino-methylcyclohexane sulphate platinum II, NSC 311056) in phase II trials. Proc ECCO 1985, 3, 84.
no DOI — not checkedKelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexane platinum (IV): an orally active platinum drug. Cancer Res 1993, 53, 2581–2586.
no DOI — not checkedInitiatives with platinum and quinazoline-based antitumor molecules. Fourteenth Bruce F. Cain Memorial Award Lecture
no DOI — not checkedSaraf N, Smith R, Brassard C, et al. Phase I trial of the oral platinum analog BMS-182751 (JM-216) in patients with refractory cancer. Proc Am Soc Clin Oncol 1996, 15, 485.
no DOI — not checkedA phase I and pharmacokinetic (PK) study of the oral platinum (Pt) analog JM216
no DOI — not checkedPagani O, Bauer J, Borner M, et al. Phase I study of the oral platinum derivative JM216 given daily for 14 days. Ann Oncol 1996, 7(Suppl 5), 125.
no DOI — not checkedGroen HJM, Smit EF, Bauer J, et al. A phase II study of oral platinum JM-216 as first-line treatment in small cell lung cancer. Proc Am Soc Clin Oncol 1996, 15, 378. Abstract.
no DOI — not checkedPeereboom DM, Wood L, Connell C, et al. Phase II trial of oral BMS-182751 (JM-216) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1997, 16, 339a.
no DOI — not checkedAssessment of response of carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity
no DOI — not checkedOrmaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin
no DOI — not checkedOverview of clinical results with ormaplatin
no DOI — not checkedCreaven PJ, Madajewicz S, Pendyala L, et al. Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine (IV) (CHIP). Cancer Treat Rep 1983, 67, 795–800.
no DOI — not checkedBramwell VHC, Crowther D, O’Malley S, et al. Activity of JM9 in advanced ovarian cancer: a phase I–II trial. Cancer Treat Rep 1985, 69, 409–416.
no DOI — not checkedSmall cell carcinoma of the lung. Phase II study of iproplatin as the single agent and combination chemotherapy of iproplatin and etoposide
no DOI — not checkedSeynaeve C, Rodenburg CJ, Von Leeuwen JTM, et al. Iproplatin (CHIP) as first-line chemotherapy in metastatic transitional cell carcinoma of the urinary tract. Proc Eur Conf Clin Oncol 1989, 5, P.0568.
no DOI — not checkedRandomized phase II trial of carboplatin vs iproplatin in solid tumors
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s0959-8049(98)00224-x"><img src="https://citestamp.com/citestamped/10.1016/s0959-8049(98)00224-x/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[00224-x/badge.svg)](https://citestamp.com/citestamped/10.1016/s0959-8049(98)00224-x)